




Title	Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behcet's disease: a large-scale, long-term postmarketing surveillance in Japan
Author(s)	Ohno, Shigeaki; Umebayashi, Itsuro; Matsukawa, Miyuki; Goto, Takashi; Yano, Toshiro
Citation	Arthritis research & therapy, 21, 2 <a href="https://doi.org/10.1186/s13075-018-1793-7">https://doi.org/10.1186/s13075-018-1793-7</a>
Issue Date	2019-01-05
Doc URL	<a href="http://hdl.handle.net/2115/73512">http://hdl.handle.net/2115/73512</a>
Rights(URL)	<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>
Type	article
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	13075_2018_1793_MOESM1_ESM.pdf (Additional file 1 )



[Instructions for use](#)



**Figure S1.** Re-infusion of IFX in BD patients who developed IRs

BD, Behçet's disease; IFX, infliximab; IRs, infusion reactions.

**Table S1.** Independent associated factors for any infections and efficacy

## Independent associated factors for any infections

	Odds ratio	95% CI	p
History of allergic disease *	2.959	1.254–6.985	0.0133
Comorbid respiratory diseases *	8.275	1.600–42.790	0.0117
Concomitant oral glucocorticoids use *	1.839	1.090–3.104	0.0225

Independent associated factors for PGA response (improved or **slightly improved**)

	Odds ratio	95% CI	p
Extraocular symptoms of BD			
<i>oral aphthous ulcers</i> *	2.097	1.224–3.590	0.0070
<i>central nervous system lesions</i> *	0.321	0.173–0.595	0.0003
<i>intestinal tract lesions</i> *	0.433	0.221–0.848	0.0147
Comorbidity			
<i>cardiac disease</i> *	0.176	0.036–0.863	0.0323
<i>diabetes mellitus</i> *	0.374	0.150–0.929	0.0342

## Independent associated factors for absence of ocular attacks after IFX treatment

	Odds ratio	95% CI	p
Severity of ocular symptoms (severe versus moderate/mild)	0.596	0.392–0.907	0.0157
Number of ocular attacks in prior 6 months (per 1 attack)	0.757	0.672–0.853	<0.0001
Extraocular symptoms of BD in skin lesions *	1.537	1.015–2.330	0.0425
Comorbid kidney disease *	3.802	1.235–11.707	0.0200
Concomitant cyclosporine use *	0.671	0.450–1.000	0.0498

\* Yes versus no. Multiple logistic regression analysis was performed to identify independent associated factors for development of any infections, response in PGA (improved or **slightly improved**); the explanatory variables used were sex, age, disease duration of BD, disease duration of uveoretinitis, severity of ocular symptoms, history of allergic disease, history of IFX treatment, extraocular symptoms of BD, comorbidities, concomitant drugs use (cyclosporine, glucocorticoids, and colchicine). In multiple logistic regression analysis for absence of ocular attacks after initiation of IFX treatment, number of ocular attacks in 6 months prior to IFX treatment was included as explanatory variables in addition to above variables. In all multiple logistic regression analysis, a stepwise selection process was used. PGA, physician global assessment; BD, Behçet's disease; IFX, infliximab.

**Table S2.** Safety profile of IFX therapy in patients with BD, RA, CD or PsO in Japanese PMS study

	BD-PMS (Day 0-180) (n=656)	BD-PMS (Day 0-730) (n=656)	RA-PMS * (6 months) (n=5,000)	CD-PMS † (1 year) (n=653)	PsO-PMS ‡ (6 months) (n=764)
Any ADRs	122 (18.60)	212 (32.32)	1401 (28.02)	93 (14.24)	172 (22.51)
<i>Blood and lymphatic system disorders</i>	0	1 (0.15)	9 (0.18)	2 (0.31)	3 (0.39)
<i>Cardiac disorders</i>	2 (0.30)	3 (0.46)	28 (0.56)	1 (0.15)	1 (0.13)
<i>Ear and labyrinth disorders</i>	0	0	2 (0.04)	0	1 (0.13)
<i>Endocrine disorders</i>	0	0	1 (0.02)	0	0
<i>Eye disorders</i>	3 (0.46)	6 (0.91)	7 (0.14)	0	1 (0.13)
<i>Gastrointestinal disorders</i>	8 (1.22)	12 (1.83)	124 (2.48)	16 (2.45)	13 (0.70)
<i>General disorders and administration site conditions</i>	15 (2.29)	31 (4.73)	275 (5.50)	7 (1.07)	29 (3.80)
<i>Hepatobiliary disorders</i>	4 (0.61)	5 (0.76)	91 (1.82)	1 (0.15)	13 (1.70)
<i>Immune system disorders</i>	2 (0.30)	3 (0.46)	10 (0.20)	1 (0.15)	2 (0.26)
<i>Infections and infestations</i>	35 (5.34)	78 (11.89)	433 (8.66)	20 (3.06)	39 (5.10)
<i>Injury, poisoning and procedural complications</i>	7 (1.07)	19 (2.90)	–	17 (2.60)	30 (3.93)
<i>Investigations</i>	18 (2.74)	30 (4.57)	223 (4.46)	9 (1.38)	27 (3.53)
<i>Metabolism and nutrition disorders</i>	1 (0.15)	2 (0.30)	8 (0.16)	1 (0.15)	1 (0.13)
<i>Musculoskeletal, and connective tissue disorders</i>	3 (0.46)	8 (1.22)	38 (0.76)	8 (1.23)	17 (2.23)
<i>Neoplasm benign, malignant, and unspecified</i>	1 (0.15)	3 (0.46)	9 (0.18)	1 (0.15)	6 (0.79)
<i>Nervous system disorders</i>	7 (1.07)	9 (1.37)	191 (3.82)	6 (0.92)	14 (1.83)
<i>Psychiatric disorders</i>	0	0	3 (0.06)	0	1 (0.13)

<i>Renal and urinary disorders</i>	0	0	12 (0.24)	0	0
<i>Reproductive system and breast disorders</i>	0	0	2 (0.04)	0	1 (0.13)
<i>Respiratory, thoracic, and mediastinal disorders</i>	12 (1.83)	29 (4.42)	141 (2.82)	8 (1.23)	11 (1.44)
<i>Skin &amp; subcutaneous tissue disorders</i>	39 (5.95)	63 (9.60)	317 (6.34)	25 (3.83)	39 (5.10)
<i>Vascular disorders</i>	0	0	115 (2.30)	2 (0.31)	2 (0.26)
<b>Serious ADRs</b>	<b>19 (2.90)</b>	<b>40 (6.10)</b>	<b>308 (6.16)</b>	<b>27 (4.13)</b>	<b>53 (6.94)</b>
<i>Blood and lymphatic system disorders</i>	0	0	6 (0.12)	0	2 (0.26)
<i>Cardiac disorders</i>	1 (0.15)	1 (0.15)	5 (0.10)	1 (0.15)	0
<i>Ear and labyrinth disorders</i>	0	0	0	0	0
<i>Endocrine disorders</i>	0	0	1 (0.02)	0	0
<i>Eye disorders</i>	1 (0.15)	2 (0.30)	0	0	0
<i>Gastrointestinal disorders</i>	1 (0.15)	1 (0.15)	13 (0.26)	7 (1.07)	3 (0.39)
<i>General disorders and administration site conditions</i>	0	2 (0.30)	26 (0.52)	2 (0.31)	8 (1.05)
<i>Hepatobiliary disorders</i>	0	0	1 (0.02)	0	3 (0.39)
<i>Immune system disorders</i>	0	1 (0.15)	10 (0.20)	1 (0.15)	1 (0.13)
<i>Infections and infestations</i>	11 (1.68)	24 (3.66)	202 (4.04)	9 (1.38)	19 (2.49)
<i>Injury, poisoning and procedural complications</i>	1 (0.15)	1 (0.15)	–	3 (0.46)	7 (0.92)
<i>Investigations</i>	0	1 (0.15)	14 (0.28)	2 (0.31)	6 (0.79)
<i>Metabolism and nutrition disorders</i>	0	0	0	0	0
<i>Musculoskeletal, and connective tissue disorders</i>	0	1 (0.15)	6 (0.12)	5 (0.77)	3 (0.39)
<i>Neoplasm benign, malignant, and unspecified</i>	1 (0.15)	2 (0.30)	9 (0.18)	1 (0.15)	4 (0.52)
<i>Nervous system disorders</i>	1 (0.15)	2 (0.30)	8 (0.16)	0	2 (0.26)
<i>Psychiatric disorders</i>	0	0	1 (0.02)	0	0

<i>Renal and urinary disorders</i>	0	0	1 (0.02)	0	0
<i>Reproductive system and breast disorders</i>	0	0	1 (0.02)	0	0
<i>Respiratory, thoracic, and mediastinal disorders</i>	3 (0.46)	4 (0.61)	40 (0.80)	2 (0.31)	5 (0.65)
<i>Skin &amp; subcutaneous tissue disorders</i>	1 (0.15)	1 (0.15)	8 (0.16)	2 (0.31)	4 (0.52)
<i>Vascular disorders</i>	0	0	3 (0.06)	1 (0.15)	0

Data are number (%). \* RA-PMS, PMS of IFX in Japanese patients with RA (MedDRA/J version 7.1); † CD-PMS, PMS of IFX in Japanese patients with CD (MedDRA/J, version 14.1); ‡ PsO-PMS; PMS of IFX in Japanese patients with PsO (MedDRA/J version 16.1). IFX, infliximab; ADRs, adverse drug reactions; BD, Behçet's disease; RA, rheumatoid arthritis; CD, Crohn's disease; PsO, psoriasis; PMS, postmarketing surveillance.

RA-PMS: Takeuchi T, et al. *Ann Rheum Dis* 2008; 67: 189–94.

PsO-PMS: Torii H, et al. *J Dermatol* 2016; 43: 767–78.

CD-PMS: Mitsubishi Tanabe Pharma Corporation internal data.